Feb 082011

The World's First Synthetic Organism

A research team, led by Craig Venter of America’s J. Craig Venter Institute (JVCI),

has successfully produced the first self-replicating, synthetic bacterial cell. Called Mycoplasma mycoides JCVI-syn1.0 the synthetic cell is the proof of principle that genomes can be designed in the computer, chemically made in the laboratory and transplanted into a recipient cell to produce a new self-replicating cell controlled only by the synthetic genome. The resulting bacterium could be regarded as the first truly synthetic organism. The researchers now hope to be able to explore the machinery of life, and to engineer bacteria designed for specific purposes such as producing drugs, biofuels or other useful chemicals.

“This is the first synthetic cell that’s been made, and we call it synthetic because the cell is totally derived from a synthetic chromosome, made with four bottles of chemicals on a chemical synthesizer, starting with information in a computer,” said Venter. “This becomes a very powerful tool for trying to design what we want biology to do. We have a wide range of applications [in mind].”

Read more . . .

Reblog this post [with Zemanta]
Jun 212010
The various levels of the scientific classific...
Image via Wikipedia

Synthetic biology can mean reconstructing organisms, redesigning biology, or recreating life—and each of these uses has different implications.

The J. Craig Venter Institute has successfully synthesized an entire bacterial genome and transplanted it into a different bacterial cell. That cell then reproduced, replicating the synthetic genome in all its progeny. Mycoplasma mycoides JCVI-syn1.0, or “Synthia” as it has become known, is an enormous technical achievement and brings the first chapter of synthetic biology to a close—a chapter in which the tools of genomic synthesis have been developed and proven. But as Venter himself has pointed out, this is not life from scratch. Other than inserting some genomic “watermarks” to sign their creation, Venter’s team closely followed nature’s pre-existing blueprints in designing their genome. The real act of creation is yet to come.

“Synthetic biology” is a catch-all label liberally applied to a host of methods for designing and constructing living things. Given the term’s multiple definitions, one of Synthia’s most immediately useful applications may be to place the achievement it represents within the context of synthetic biology’s various flavors, in order to clarify what the creation of artificial life might actually mean.

Reconstructing an organism

Synthia is a reconstruction of a living thing. Venter and his colleagues wanted to demonstrate that it is possible to synthesize an entire genome indistinguishable in function and identical in every way to its natural counterpart (except for the additional watermarks). By increasing the power and widening the scope of synthesis to encompass an entire genome, Venter and his team may well have enabled a whole host of future discoveries. However, because Synthia is a copy of an existing bacterium, it gives us little clue as to the actual potential for designing organisms in the future. Synthia is primarily a proof of concept. The next challenge is to design every aspect of an organism’s genome by mixing and matching any genes found in nature.

Read more . . .

Enhanced by Zemanta
May 262010
John Sulston
Image via Wikipedia

A top UK scientist who helped sequence the human genome has said efforts to patent the first synthetic life form would give its creator a monopoly on a range of genetic engineering.

Professor John Sulston said it would inhibit important research.

US-based Dr Craig Venter led the artificial life form research, details of which were published last week.

Prof Sulston and Dr Venter clashed over intellectual property when they raced to sequence the genome in 2000.

Craig Venter led a private sector effort which was to have seen charges for access to the information. John Sulston was part of a government and charity-backed effort to make the genome freely available to all scientists.

“The confrontation 10 years ago was about data release,” Professor Sulston said.

“We said that this was the human genome and it should be in the public domain. And I’m extremely glad we managed to pull this out of the bag.”

‘Range of techniques’

Now the old rivals are at odds again over Dr Venter’s efforts to apply for patents on the artificially created organism, nicknamed Synthia. The team outlined the remarkable advance last week in the prestigious journal Science.

But Professor Sulston, who is based at the University of Manchester, said patenting would be “extremely damaging”.

“I’ve read through some of these patents and the claims are very, very broad indeed,” Professor Sulston told BBC News.

“I hope very much these patents won’t be accepted because they would bring genetic engineering under the control of the J Craig Venter Institute (JCVI). They would have a monopoly on a whole range of techniques.”

Read more . . .

Reblog this post [with Zemanta]